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Melatonin is an endogenous hormone mainly produced by the pineal gland whose dys-
function leads to abnormal sleeping patterns. Changes in melatonin have been reported
in acute traumatic brain injury (TBI); however, the impact of environmental conditions typ-
ical of the intensive care unit (ICU) has not been assessed. The aim of this study was to
compare daily melatonin production in three patient populations treated at the ICU to differ-
entiate the role ofTBI versus ICU conditions. Forty-five patients were recruited and divided
into severe TBI, trauma without TBI, medical conditions without trauma, and compared to
healthy volunteers. Serum melatonin levels were measured at four daily intervals at 0400 h,
1000 h, 1600 h, and 2200 h for 7 days post-ICU admission by commercial enzyme linked
immunosorbent assay. The geometric mean concentrations (95% confidence intervals) of
melatonin in these groups showed no difference being 8.3 (6.3–11.0), 9.3 (7.0–12.3), and
8.9 (6.6–11.9) pg/mL, respectively, in TBI, trauma, and intensive care cohorts. All of these
patient groups demonstrated decreased melatonin concentrations when compared to con-
trol patients.This study suggests thatTBI as well as ICU conditions, may have a role in the
dysfunction of melatonin. Monitoring and possibly substituting melatonin acutely in these
settings may assist in ameliorating long-term sleep dysfunction in all of these groups, and
possibly contribute to reducing secondary brain injury in severe TBI.
Keywords: melatonin,TBI, trauma, intensive care unit, circadian
INTRODUCTION
Traumatic brain injury (TBI) remains a significant medical con-
cern worldwide as a considerable cause of permanent disability,
imposing a significant burden on society. Despite improvements
in neurosurgery and intensive care treatment, mortality in severe
TBI patients remains high (1, 2).
A common consequence of brain trauma is sleep disturbance
including insomnia and altered sleep–wake cycles (3, 4). In the
long term, sleep disturbance is associated with fatigue, depression,
anxiety, and cognitive dysfunction likely due to lower evening
melatonin levels (5, 6). Deficiencies in sleep may also impair
recovery from brain injury by increasing catabolic rate, decreas-
ing cellular and humoral immunity, and impairing cell division
and thus compromising quality of life (7). Sleep duration and
quality in intensive care unit (ICU) patients has been linked to
abnormal melatonin production (7, 8). Endogenous melatonin
is produced by the pineal gland and regulates the sleep–wake
cycle (9, 10). The blood concentrations of melatonin increase
between 0200 h and 0400 h (11) and decrease to a nadir during
daylight hours. When administered, exogenous melatonin is able
to induce phase shifts of the circadian rhythm of the sleep–wake
cycle (10, 12).
In addition to its physiological roles in regulating sleep patterns,
melatonin has been demonstrated to provide neuroprotective
effects in brain injury models due to its pleiotropic properties (13–
15). Its therapeutic potential has been shown to provide protection
by stabilizing endothelial permeability and limiting the extent of
brain edema and by reducing oxidative stress and neuronal death
following injury (16–19).
The above findings have prompted the hypothesis that thera-
peutic application of melatonin might improve patient recovery
by restoring the circadian rhythm of the sleep–wake cycle and
counteract the neurotoxic biochemical cascades leading to sec-
ondary brain damage. We previously published data showing that
increased cerebrospinal fluid levels of melatonin were associated
with heightened isoprostane levels, a biomarker of oxidative stress,
suggesting that a possible role of melatonin to combat oxida-
tive stress (20). However, serum concentrations of melatonin
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measured only at one time point daily were found unchanged.
Thus, to deepen our understanding on the impact of TBI on mela-
tonin production, we embarked on a study to measure melatonin
levels over four time intervals during the day and elucidate whether
their alterations are specifically attributable to brain injury and/or
to critical care circumstances.
MATERIALS AND METHODS
PATIENTS AND BLOOD SAMPLING
This study was conducted in accordance with the National Health
and Medical Research Council of Australia national statement
on ethical conduct in research involving human beings and has
been approved by The Alfred Hospital Human Ethics Committee.
Informed consent was waived on admission and delayed writ-
ten consent was obtained from either the patient or the next
of kin.
Forty-five patients admitted to the ICU at The Alfred, Mel-
bourne, were recruited to one of three groups: patients with severe
TBI defined as a Glasgow coma scale (GCS) score of<9 on admis-
sion, patients having sustained extra-cranial traumatic injury but
no brain injury, and patients admitted to the ICU for conditions
other than trauma. Healthy volunteers were used for control mea-
sures. Details of the patients in terms of demographics and GCS
are given in Table 1.
Upon recruitment, all patients underwent serial serum at
0400 h, 1000 h, 1600 h, and 2200 h. Sampling began at the next
scheduled interval once the patient had been recruited. The serum
samples were centrifuged for 10 min at 4°C at 200× g and stored at
−80°C. Sampling continued for up to 8 days until the patient was
discharged from ICU, and the extended Glasgow outcome scale
(GOSE) was assessed at six months following admission.
Table 1 | Epidemiological characteristics including age, gender, GCS,
and GOSE where relevant, and mean/range of melatonin levels in
three patient groups: severeTBI; trauma without severeTBI; medical




Number of patients 18 14 13 45
Age
Mean±SEM 35.1±3.2 50.7±4.9 43.9±4.9 42.5±2.6
(range) (16–73) (21–86) (22–74) (16–86)
Gender
Male (%) 14 (78%) 13 (93%) 7 (54%) 34 (76%)




Geometric mean 8.3 9.3 8.9 8.9
(95% CI) (6.3–11.0) (7.0–12.3) (6.6–11.9) (7.4–10.7)
Melatonin production over four intervals per day for seven consecutive days post-
admission in ICU was calculated and showed no statistical difference among the
groups (p=0.87).
MEASUREMENT OF MELATONIN
Serum melatonin concentrations were measured using a com-
mercially available melatonin competitive binding enzyme linked
immunosorbent assay (ELISA) kit (IBL Immunological Labora-
tories, Hamburg, Germany) as previously described (20). The
kit used has a minimum detection limit of 1.5 pg/mL with an
intra-assay coefficient of variance of 3.0–11.4% and an inter-assay
coefficient of variance range of 6.4–19.3%.
STATISTICAL ANALYSIS
For the purposes of interpretation, day 1 is calculated as the day of
admission to the ICU, beginning at 0000 h. Serum melatonin was
found to be well approximated by a lognormal distribution so was
log-transformed prior to analysis with results presented as geomet-
ric means [95% confidence intervals (CI)]. Longitudinal analysis
of melatonin was performed using mixed linear modeling (PROC
MIXED) with log-melatonin as the outcome and fixed main cate-
gorical effects for Group (A, B, or C), Time (0400 h, 1000 h, 1600 h,
and 2200 h) and Day (1–8), with each patient treated as a random
effect. To ascertain if time and day effects were consistent across
groups, interaction between group and time and group and day
were explored. Patient age and gender along with assay number
were also examined but were not included in final models due to
the lack of any apparent significant relationship with melatonin.
All analysis was performed using SAS version 9.2 (SAS Institute,
Inc., Cary, NC, USA).
RESULTS
PATIENT CHARACTERISTICS
In total 45 patients were recruited into this study. Overall, the
ages of the patients ranged from 16 to 86 years with a mean age
of 42.5± 2.6 years. There was a male predominance, with a 34:11
ratio of males to females. Patients were enrolled in the study for up
to 8 days from ICU admission and occurrence of TBI. As described,
patients were recruited into three arms of the trial: patients admit-
ted to the ICU with severe TBI defined as a GCS score of <9;
patients admitted to the ICU having sustained trauma but with-
out severe TBI; and patients admitted to the ICU without a history
of trauma or severe TBI (see Table 1). Patients with trauma
but not TBI sustained injuries including fractures of the long
bones, vertebrae, or facial bones; pneumothoraces; pulmonary
and cardiac contusions; intra-abdominal visceral injuries; and soft
tissue injuries including lacerations and contusions. Patients in
this group included those who had sustained intracranial injuries
but had a GCS of at least 9. Patients admitted to ICU without
trauma or TBI demonstrated conditions including infective endo-
carditis, perforated abdominal viscera, pneumonia, acute myocar-
dial infection, and exacerbation of chronic conditions including
asthma.
All patients in this study underwent individually patient-
centered treatment in the ICU. There were no alterations in
treatment afforded these patients due to their inclusion in
this study. As part of their standard therapeutic regimens,
they might have been administered any of barbiturate therapy,
anti-epileptic therapy, non-steroidal anti-inflammatory medica-
tions, pharmacological sedation, and induced coma. Of note,
the ICU does have different lighting conditions depending
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upon day/night, with a lower level of ambient lighting during
the night.
SEVERE TBI
Over the study period, 18 patients having sustained severe TBI
were included in the TBI arm. There were 14 males and 4 females,
with a mean age of 35.1± 3.2 (16–73). The mechanisms for injury
included predominantly motor vehicle accidents (6, 33%), fol-
lowed by motorcycle accidents (2, 11%), pedestrian (2, 11%), fall
from height >2 m (1, 6%), assault (1, 6%), other (5, 28%), and
one unknown (6%). There was a range of GCS with a mean of
5.5± 0.8.
The temporal profile of serum melatonin for this group is
shown in Figure 1, with geometric mean concentrations (95%
CI) displayed for each timepoint measured. Daily maximum val-
ues were demonstrated as might be expected at night time: 2200 h
on day 1 and 0400 h on all other days; whereas local minimum
melatonin concentrations were evidenced during the daytime
at 1000 h on all days apart from day 3, when a minimum was
demonstrated at 1600 h.
TRAUMAWITHOUT SEVERE TBI (TRAUMA)
Fourteen patients who sustained traumatic injuries without severe
TBI were included in the study. In this group, 14 suffered multi-
trauma, with those sustaining TBI demonstrating a GCS score
≥9. There were 13 males and 1 female, exhibiting a mean age of
50.7± 4.9 years (21–86 years). Again, motor vehicle accidents were
most common in this group, occurring in 8 (57%) of patients, fol-
lowed by motorcycle accidents (2, 14%), fall from height (1, 7%),
assault (1, 7%), cyclist (1, 7%), and other (1, 7%). The mean GCS
was 13.2± 0.7.
As shown in Figure 2, daily maximum melatonin levels were
demonstrated at 0400 h on days 2–5, 7, and at 2200 h on day 6.
Local minimum values were exhibited at 1000 h on days 1–3, 6–7,
at 1600 h on day 5, and at 2200 h on day 4.



















































































































































































Temporal profile of melatonin in TBI patients  
FIGURE 1 |Temporal profile of geometric mean serum melatonin concentrations inTBI patients, with peaks at 2200 h on Day 1 and 0400 h on Day 8,
















































































































































































Temporal profile of melatonin in trauma patients  
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
FIGURE 2 |Temporal profile of geometric mean serum melatonin concentrations in trauma patients withoutTBI, with peaks at 0400 h on Days 2, 3, 4,
5, and 7, and nadir at 1600 h on Day 5.


































































































































































































































Temporal profile of melatonin in ICU patients 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
FIGURE 3 |Temporal profile of geometric mean serum melatonin concentrations in ICU patients, with peaks at varying times on the initial 3 days,


































































Temporal profile of melatonin for control patients 
FIGURE 4 |Temporal profile of mean serum melatonin concentrations in controls, with a diurnal variation displaying maximum values at
night, and minimum values during the day (p<0.0001). The geometric mean concentrations for the control patients are significantly higher than
those of the other patient groups.
ICU WITHOUT TRAUMA OR TBI
Over the study period, 13 patients treated in ICU without hav-
ing sustained any form of head injury or trauma were included
in the third group. There were seven males and six females, with
a mean age of 43.9± 4.9 (22–74). Three of these patients sus-
tained neurosurgical insults with two patients presenting with a
World Federation of Neurological Surgeons grade V subarachnoid
hemorrhage, and one with an intracerebral hemorrhage, with no
history of trauma.
The temporal profile of serum melatonin for this group (see
Figure 3) demonstrates geometric mean concentrations (95%
CI) displayed for each timepoint measured. Daily maximum val-
ues were demonstrated at 2200 h on day 1, and 0400 h on all
other days; whereas minimum melatonin concentrations were evi-
denced at 2200 h on days 2 and 6, 1600 h on days 3–5, and 1000 h
on day 7.
CONTROL PATIENTS
In order to provide appropriate comparisons, six healthy peo-
ple were recruited as control patients for this study. The control
patients were healthy volunteers with no neurological conditions
and on no medications, recruited from our laboratory. The control
patients had serum samples taken every 6 h for a single 24-h period.
The temporal profile of control patients is shown in Figure 4. The
geometric mean serum melatonin concentrations ranged from 6.6
to 155.6 pg/mL with an overall geometric mean value of 27.0
(16.3–44.6) pg/mL. This range of serum melatonin concentrations
differs somewhat to those reported in the literature of 7.4–82.5 (11,
21, 22) and the mean control serum melatonin concentration of
15.15± 1.65 pg/mL that this group has reported previously (20).
However, it is important to note that Rizzo et al. (21) demon-
strated melatonin concentrations ranging up to 163 pg/mL (21),
and there is very little consistency in terms of sample collec-
tion methodology and analytical techniques among the studies
we found in the literature. As expected under physiological con-
ditions, endogenous melatonin concentrations were at a peak at
0400 h, with a mean value of 155.6 pg/mL, decreasing to daytime
lows of 8.8 pg/mL at 1000 h and 6.6 pg/mL at 1600 h, before again
rising at 2200 h. The profile of melatonin in this group coincides
with normal physiological fluctuations in a day cycle.
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COMPARISONS OF ALL ICU PATIENT GROUPS
Overall, when comparing the three groups, there was no statis-
tically significant difference between the geometric mean mela-
tonin concentrations analyzed via generalized linear modeling
(p= 0.87). Regarding the CI of each group, there was little dif-
ference between the groups, with trauma and ICU both demon-
strating a 95% CI of 5.3 pg/mL, and TBI patients a slightly smaller
(yet not significant) 95% CI of 4.7 pg/mL, suggesting that a consis-
tently homogenous variation of melatonin production across the
groups. The geometric mean melatonin concentrations of each
of the patient groups were demonstrated to be significantly lower

















































Timepoints for all groups 
FIGURE 5 | Comparison graph of time point effect. Night-time
timepoints (0400 h and 2200 h) were significantly elevated compared to
daytime time points, and 0400 h significantly higher than 2200 h.
There was an overall time effect (p< 0.0001), with the highest
melatonin concentrations tending to occur at 0400 h, and the low-
est at 1600 h (Figure 5). There was a day effect demonstrated, with
day 1 most commonly exhibiting significantly higher melatonin
concentrations than other days (p< 0.05) (Figure 6). An interac-
tion between groups and timepoints was investigated, attempting
to determine whether the time effect differed between groups,
although this was not significant (p= 0.11). Similarly, there was
no significant interaction between group and day (p= 0.56).
DISCUSSION
This study demonstrated a marked disruption of the diurnal
rhythm in the TBI patients and the ICU patients,which resumed its
normal pattern by the third day. Physiological studies have demon-
strated that melatonin levels peak between 0200 h and 0400 h (11),
and decrease toward their nadir during the day. However, in our
study derangement of this rhythm was noted, in particular, during
the first days measured.
Patients having sustained trauma but not TBI demonstrated
a consistent peak melatonin concentration with a similar level at
0400 h on each day of the study, with the sole exception of day
6. The values of this group may thus be generalized as main-
taining their circadian rhythm, with peaks occurring at 0400 h
on each day. In contrast to trauma patients, both TBI and ICU
patient groups demonstrated a clear disruption to the physiolog-
ical pattern of melatonin concentrations. Patients with TBI first
restored a maximal melatonin level on day 2 at 0400 h, albeit lower
than the previous timepoint of 2200 h on day 1. This maximal
level was also lower than the physiological levels at this time of
149 pg/mL in our controls and 163 pg/mL in the literature, after
which the peak was maintained at 0400 h on each successive day
of the study. Similarly, while the maximal daily melatonin con-
















































Temporal profile of melatonin for all groups 
FIGURE 6 | Comparison graph of day effect. Day 1 values were significantly elevated when compared with days 2–6.
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restoration of the diurnal melatonin fluctuation did not take place
until day 4.
It has already been established that the circadian rhythm of
melatonin production is disrupted following both TBI and ICU
admission (5, 8). However, what has not been elucidated, to date,
to our knowledge, is whether trauma patients without severe TBI
share this derangement or whether they remain relatively unaf-
fected. From our data, it would appear that serum melatonin
concentrations for patients who have sustained significant trauma
(enough to warrant ICU admission) maintain their pattern of
melatonin levels and thus a normal circadian rhythm.
Furthermore, our data suggest that a disruption of circadian
rhythm of melatonin concentrations in the TBI patients. While
demonstrating a maximal concentration at 0400 h on day 2, these
patients only appear to “correct” their pattern by day 3. Many
theories have been postulated as to the mechanisms behind this
derangement, in view of melatonin’s effects as a neuroprotective
agent. It may be postulated that imbalance in melatonin pro-
duction and consumption, as well as any alteration of pineal
gland function is a complex sequel of the general neuroendocrine
dysfunction detected in TBI patients that affects the pituitary,
hypothalamus, and their axes (23). Whether melatonin may be
produced in response to the injury, depleted as it exerts its neuro-
protective effects, or is further produced as a result of this depletion
is unknown, and the design of this study does not allow for inves-
tigation of these hypotheses. However, it remains plausible that
the consumption of endogenous melatonin in the attempt to
counteract deleterious sequelae of TBI may disrupt the physio-
logical circadian rhythm which, in turn, may result in the sleep
disturbances witnessed in TBI patients (5).
Similarly, ICU patients exhibit alteration of expected melatonin
profiles until day 3. Potential factors involved in this disruption
include performance of medical procedures at all hours, and high
noise levels, as well as the continuous monitoring of vital signs
(8). In many ICUs, high intensity of ambient light is present
even at night, however, in the ICU in which the study was under-
taken, there is decreased light during nocturnal hours to respect a
more physiological day/night rhythm. Despite this, there remain
factors, which might influence the physiological production of
melatonin in this setting. As such, this derangement would be
anticipated to continue at least until the patients had been dis-
charged from the ICU, however, this was witnessed only until day
3 after which time the rhythm was restored but not the physi-
ological concentrations of melatonin. It may be postulated that
following the initial disruption to the circadian rhythm, the body
resynchronizes its melatonin production accordingly, though the
mechanisms leading to this phenomenon remain obscure.
There were some interesting characteristics borne out in the
temporal profiles. All of the three groups demonstrated similar
minimum concentrations, with the minimum geometric mean
melatonin concentrations varying by 0.7 pg/mL between the three
groups. However, the maximum levels demonstrated greater varia-
tion of 20.9 pg/mL across the groups, with TBI patients and trauma
patients having similar maximum geometric mean melatonin con-
centrations, and ICU patients a greater maximum value. When
looking specifically at the 95% CI, all groups were similar with TBI
patients demonstrating a range of 4.7 pg/mL, and both trauma and
ICU patients 5.3 pg/mL.
The values exhibited in TBI and trauma patients when con-
trasted against ICU patients, support the potential impact of
trauma in endogenous melatonin concentrations. While not
clearly understood, it appears that melatonin levels are altered
in these settings. These derangements have been previously attrib-
uted to conditions such as the ambient lighting in ICU and the
continual disruption of patients’ sleep by medical, nursing, and
monitoring needs. This study has not been designed to investigate
the precise causative factors for these derangements.
Our study demonstrates that all groups exhibit lower melatonin
concentrations than control patients. This finding is in contrast
with our previous study, which demonstrated that single daily
measurements of serum melatonin levels were not significantly
increased in TBI comparative to controls (20), though it may be
argued that this study is more appropriately designed to iden-
tify these differences. The precise pathophysiological processes
underlying the decreases in serum melatonin for all our patient
groups is unclear, and it may, in fact, be that all patients with
significant illness have decreased melatonin, be it as a result of
increased consumption, lack of production, or a combination of
the two. However, it must be noted that there is great difficulty in
performing accurate comparisons between our current and pre-
vious studies. There was a significant difference in our sampling
techniques and times between the two studies (the current study
comprise four separate sampling timepoints of serum, whereas the
previous study comprised a single sampling at 0900 h) (20).
Sleep disturbances (4) and, in fact, delayed circadian rhythms
have been reported in patients with mild TBI (24) and also severe
TBI (5). In a study performed by Shekleton et al., salivary concen-
trations of endogenous melatonin were collected overnight every
half hour in patients with TBI, and correlated with polysomno-
graphic sleep recording. Patients with TBI demonstrated sleep dis-
turbances as well as decreased melatonin concentrations overnight
(5). Ponsford et al. showed long-term deficiency of sleep patterns
associated with fatigue in TBI patients (6). To this end, a clinical
trial is currently underway wherein children suffering from post-
concussion syndrome receive sublingual melatonin for a month
post-event (25) in an attempt to reduce symptoms following TBI.
It might be that the degree of TBI impacts particularly on the cir-
cadian rhythm, though this remains speculation at this point in
time.
While this study aimed to provide a temporal profile of endoge-
nous melatonin concentrations throughout the duration of a
patient’s admission to ICU, the maximum length of stay was only
8 days. The collection of serum samples at four time points of each
day was able to afford detailed insight into the variation of levels
throughout a 24-h period; however, it may be inadequate in dura-
tion for investigating the response of endogenous melatonin over
a longer time period. A further confounding factor might be the
inclusion of patients with brain injury in the ICU patient group.
Despite these patients not having sustained TBI, they nonethe-
less did suffer brain injury, and this may have impacted upon the
melatonin concentrations in these patients. Furthermore, owing
to the small group sizes, there is a degree of increased variation in
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values. Similarly, our control patient values demonstrated signif-
icant variation between day and night time values, which might
have been addressed by increased control patient numbers. Despite
these limitations to our study, we feel that this work is able to con-
tribute to an understanding of the temporal profile of melatonin
following TBI and in the ICU patient.
CONCLUSION
This study aims to further elucidate the temporal profile of mela-
tonin in patients with severe TBI, trauma without severe head
injury, and ICU patients. There are derangements of the circadian
rhythm of melatonin production in patients undergoing severe
head injury, and decreased concentrations in patients with both
severe TBI and trauma without severe head injury when compared
to controls. It remains likely that these derangements may be due,
in part, to alterations in melatonin production and/or metabolism,
or to the deleterious effects of oxidative stress and the physiological
damage imposed by TBI. This study provides valuable data regard-
ing temporal profiles of melatonin, which might, in the future, be
used to target therapeutic potentials of melatonin administration
in patients having sustained severe TBI.
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